摘要
目的:探讨曲妥珠单抗(赫赛汀)联合吉西他滨(GEM)治疗表皮生长因子受体2(HER2)阳性的转移性乳腺癌(MBC)的疗效和不良反应。方法:HER2阳性的MBC女性患者9例,给予GEM1 000mg/m2,静脉滴注,d1、d8、d15,4周重复;赫赛汀静脉滴注,首次4mg/kg,其后每周1次,2mg/kg,连续使用。结果:9例患者中,CR 1例(11.1%),PR 6例(66.7%),SD和PD各1例(11.1%),有效率(RR)为77.8%,疾病控制率(DCR)为88.9%;中位肿瘤进展时间(TTP)为18个月,中位总生存时间(OS)为23个月。主要毒性反应是骨髓抑制和消化道反应,且均为Ⅰ～Ⅱ度。结论:赫赛汀联合吉西他滨对于难治性转移性乳腺癌是有效且安全的治疗方案。
Objective：To evaluate the efficacy and safety of trastuzumab in combination with gemcitabine as salvage therapy in metastatic breast cancer with Her2-positive.Methods：Nine consecutive patients were included as eligible.Patients received gemcitabine at a dose of 1 000mg/m2 on day 1,8,15,every 28 days.Trastuzumab was given at initial dose of 4mg/kg,followed by weekly infusions at the dose of 2mg/kg.Results：In those patients,11.1% patients with CR（1/9）,66.7% patients with PR（6/9）.The disease control rate was 88.9%,and the medina time of tumor progression（TTP） was 18 months,and the medina time of overall survival was 23 months.The major grade 1-2 toxicities were myelosuppression and gastrointestinal reactions.Conclusion：Trastuzumab in combination with gemcitabine has clinically significant activity and safety in patients with refractory metastatic breast cancer.
出处
《临床肿瘤学杂志》
CAS
2009年第10期916-918,共3页
Chinese Clinical Oncology
作者简介
通讯作者：E-mail：qinsk@csco.org.cn
